Literature DB >> 26207206

First-line nivolumab (anti-PD-1) monotherapy in advanced NSCLC: the story of immune checkpoint inhibitors and "the sorcerers apprentice".

Gerald Schmid-Bindert1, Tao Jiang1.   

Abstract

Entities:  

Year:  2015        PMID： 26207206      PMCID： PMC4483480          DOI： 10.3978/j.issn.2218-6751.2015.01.12

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  1 in total

1.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245
  1 in total
  7 in total

1.  The continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung.

Authors:  Wan Ling Tan; Quan-Sing Ng
Journal:  Transl Lung Cancer Res       Date:  2016-02

2.  Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data.

Authors:  Gustavo Dix Junqueira Pinto; Luciano de Souza Viana; Cristovam Scapulatempo Neto; Sérgio Vicente Serrano
Journal:  J Immunol Res       Date:  2016-09-22       Impact factor: 4.818

3.  Dynamics of Heat Shock Protein 70 Serum Levels As a Predictor of Clinical Response in Non-Small-Cell Lung Cancer and Correlation with the Hypoxia-Related Marker Osteopontin.

Authors:  Christian Ostheimer; Sophie Gunther; Matthias Bache; Dirk Vordermark; Gabriele Multhoff
Journal:  Front Immunol       Date:  2017-10-18       Impact factor: 7.561

4.  Nivolumab, a new immunomodulatory drug, a new adverse effect; adrenal crisis.

Authors:  Funda Karbek Akarca; Ozge Can; Sercan Yalcinli; Yusuf Ali Altunci
Journal:  Turk J Emerg Med       Date:  2017-06-20

Review 5.  EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.

Authors:  Shuhang Wang; Stella T Tsui; Christina Liu; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2016-07-22       Impact factor: 17.388

6.  Bilateral uveitis and macular edema induced by Nivolumab: a case report.

Authors:  Claire Theillac; Morgane Straub; Anne-Laure Breton; Luc Thomas; Stéphane Dalle
Journal:  BMC Ophthalmol       Date:  2017-12-01       Impact factor: 2.209

7.  Effective antitumor peptide vaccines can induce severe autoimmune pathology.

Authors:  Hussein Sultan; Jimena Trillo-Tinoco; Paulo Rodriguez; Esteban Celis
Journal:  Oncotarget       Date:  2017-07-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.